Vestis Corporation (VSTS) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

PR Newswire


LOS ANGELES
, June 27, 2025 /PRNewswire/ — Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Vestis Corporation (“Vestis” or the “Company”) (NYSE: VSTS).

IF YOU SUFFERED A LOSS ON YOUR VESTIS INVESTMENTS, CLICK 

HERE

 BEFORE AUGUST 8, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT

What Is The Lawsuit About?

The complaint filed alleges that, between May 2, 2024, to May 6, 2025, Defendants failed to disclose to investors that: (1) the Company was not equipped to achieve its growth guidance as the realization of these efforts instead resulted in a significant decline of revenue from existing customers; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email:  [email protected]
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased. 

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:

Glancy Prongay
& Murray LLP
1925 Century Park East, Suite 2100,
Los Angeles, CA 90067
Charles Linehan
Email:  [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vestis-corporation-vsts-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302492913.html

SOURCE Glancy Prongay & Murray LLP

Franklin Universal Trust (“FT” or the “Fund”) Announces Notification of Sources of Distributions

Franklin Universal Trust (“FT” or the “Fund”) Announces Notification of Sources of Distributions

SAN MATEO, Calif.–(BUSINESS WIRE)–
Franklin Universal Trust [NYSE: FT]:

Notification of Sources of Distributions

Pursuant to Section 19(a) of the Investment Company Act of 1940 

The Fund’s estimated sources of the distribution to be paid on June 30, 2025, and for the fiscal year 2025 year-to-date are as follows:

Estimated Allocations for June Monthly Distribution as of May 31, 2025:

Distribution

Per Share

Net Investment

Income

Net Realized

Short-Term Capital

Gains

Net Realized

Long-Term Capital

Gains

Return of

Capital

$0.0425

$0.0345 (81%)

$0.00 (0%)

$0.00 (0%)

$0.0080 (19%)

Cumulative Estimated Allocations fiscal year-to-date as of May 31, 2025, for the fiscal year ending August 31, 2025:

Distribution

Per Share

Net Investment

Income

Net Realized

Short-Term Capital

Gains

Net Realized

Long-Term Capital

Gains

Return of

Capital

$0.3825

$0.2483 (65%)

$0.00 (0%)

$0.00 (0%)

$0.1342 (35%)

Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution or from the terms of the Fund’s Distribution Policy. FT estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of the FT distribution to shareholders may be a return of capital. A return of capital may occur, for example, when some or all of the money that a shareholder invested in a Fund is paid back to them. A return of capital distribution does not necessarily reflect FT’s investment performance and should not be confused with ‘yield’ or ‘income’. The amounts and sources of distributions reported herein are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send a Form 1099-DIV to shareholders for the calendar year that will describe how to report the Fund’s distributions for federal income tax purposes.

Average Annual Total Return (in relation to the change in net asset value (NAV) for the 5-year period ended on 5/31/2025)1

Annualized Distribution Rate (as a percentage of NAV for the current fiscal period through 5/31/2025)2

Cumulative Total Return (in relation to the change in NAV for the fiscal period through 5/31/2025)3

Cumulative Fiscal Year-To-Date Distribution Rate (as a percentage of NAV as of 5/31/2025)4

8.27%

6.20%

4.99%

4.65%

Fund Performance and Distribution Rate Information:

  1. Average Annual Total Return in relation to NAV represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ended through May 31, 2025. Annual NAV Total Return is the percentage change in the Fund’s NAV over a year, assuming reinvestment of distributions paid.
  2. The Annualized Distribution Rate is the current fiscal period’s distribution rate annualized as a percentage of the Fund’s NAV through May 31, 2025.
  3. Cumulative Total Return is the percentage change in the Fund’s NAV from August 31, 2024 through May 31, 2025, assuming reinvestment of distributions paid.
  4. The Cumulative Fiscal Year-To-Date Distribution Rate is the dollar value of distributions for the fiscal period August 31, 2024 through May 31, 2025, as a percentage of the Fund’s NAV as of May 31, 2025.

The Fund’s primary investment objective is to provide high, current income consistent with preservation of capital. Its secondary objective is growth of income through dividend increases and capital appreciation. Distributions may vary based on the Fund’s net investment income. Past distributions are not indicative of future trends.

For further information on Franklin Universal Trust, please visit our web site at: www.franklintempleton.com

Franklin Resources, Inc. is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. Through its specialist investment managers, the company offers specialization on a global scale, bringing extensive capabilities in fixed income, equity, alternatives and multi-asset solutions. With more than 1,500 investment professionals, and offices in major financial markets around the world, the California-based company has over 75 years of investment experience and $1.57 trillion in assets under management as of May 31, 2025. For more information, please visit franklintempleton.com.

For more information, please contact Franklin Templeton at 1-800-342-5236.

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

Notification of Sources of Distributions

Pursuant to Section 19(a) of the Investment Company Act of 1940

The Fund’s estimated sources of the distribution to be paid on June 30, 2025, and for the fiscal year 2025 year-to-date are as follows:

Estimated Allocations for June Monthly Distribution as of May 31, 2025:

Distribution Per Share

Net Investment Income

Net Realized Short-Term Capital Gains

Net Realized Long-Term Capital Gains

Return of Capital

$0.0615

$0.0336 (55%)

$0.0018 (3%)

$0.00 (0%)

$0.0261 (42%)

Cumulative Estimated Allocations fiscal year-to-date as of May 31, 2025, for the fiscal year ending December 31, 2025:

Distribution Per Share

Net Investment Income

Net Realized Short-Term Capital Gains

Net Realized Long-Term Capital Gains

Return of Capital

$0.3075

$0.2096 (68%)

$0.00 (0%)

$0.00 (0%)

$0.0979 (32%)

The Fund has experienced a cumulative loss in undistributed net realized and unrealized capital gains and losses totaling $1.4215 per share. Of that amount, $0.5139 per share represents unrealized depreciation of portfolio securities.

Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution or from the terms of the Fund’s Plan. FTF estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of the FTF distribution to shareholders may be a return of capital. A return of capital may occur, for example, when some or all of the money that a shareholder invested in a Fund is paid back to them. A return of capital distribution does not necessarily reflect FTF’s investment performance and should not be confused with ‘yield’ or ‘income’. The amounts and sources of distributions reported herein are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send a Form 1099-DIV to shareholders for the calendar year that will describe how to report the Fund’s distributions for federal income tax purposes.

Average Annual Total Return (in relation to the change in net asset value (NAV) for the 5-year period ended on 5/31/2025)1

Annualized Distribution Rate (as a percentage of NAV for the current fiscal period through 5/31/2025)2

Cumulative Total Return (in relation to the change in NAV for the fiscal period through 5/31/2025)3

Cumulative Fiscal Year-To-Date Distribution Rate (as a percentage of NAV as of 5/31/2025)4

4.65%

10.87%

2.33%

4.53%

Fund Performance and Distribution Rate Information:

1

Average Annual Total Return in relation to NAV represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ended through May 31, 2025. Annual NAV Total Return is the percentage change in the Fund’s NAV over a year, assuming reinvestment of distributions paid.

2

The Annualized Distribution Rate is the current fiscal period’s distribution rate annualized as a percentage of the Fund’s NAV through May 31, 2025.

3

Cumulative Total Return is the percentage change in the Fund’s NAV from December 31, 2024 through May 31, 2025, assuming reinvestment of distributions paid.

4

The Cumulative Fiscal Year-To-Date Distribution Rate is the dollar value of distributions for the fiscal period (December 31, 2024 through May 31, 2025), as a percentage of the Fund’s NAV as of May 31, 2025.

The Fund’s Board of Trustees (the “Board”) has authorized a managed distribution plan (the “Plan”) pursuant to which the Fund makes monthly distributions to shareholders at the fixed rate of $0.0615 per share. The Plan is intended to provide shareholders with consistent distributions each month and is intended to narrow the discount between the market price and the net asset value (“NAV”) of the Fund’s common shares, but there can be no assurance that the Plan will be successful in doing so. The Fund is managed with a goal of generating as much of the distribution as possible from net ordinary income and short-term capital gains, that is consistent with the Fund’s investment strategy and risk profile. To the extent that sufficient distributable income is not available on a monthly basis, the Fund will distribute long-term capital gains and/or return of capital in order to maintain its managed distribution rate. A return of capital may occur, for example, when some or all of the money that was invested in the Fund is paid back to shareholders. A return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with “yield” or “income”. Even though the Fund may realize current year capital gains, such gains may be offset, in whole or in part, by the Fund’s capital loss carryovers from prior years.

The Board may amend the terms of the Plan or terminate the Plan at any time without prior notice to the Fund’s shareholders. The amendment or termination of the Plan could have an adverse effect on the market price of the Fund’s common shares. The Plan will be subject to the periodic review by the Board, including a yearly review of the fixed rate to determine if an adjustment should be made.

For further information on Franklin Limited Duration Income Trust, please visit our web site at: www.franklintempleton.com

Franklin Resources, Inc. is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. Through its specialist investment managers, the company offers specialization on a global scale, bringing extensive capabilities in fixed income, equity, alternatives and multi-asset solutions. With more than 1,500 investment professionals, and offices in major financial markets around the world, the California-based company has over 75 years of investment experience and $1.57 trillion in assets under management as of May 31, 2025. For more information, please visit franklintempleton.com.

For more information, please contact Franklin Templeton at 1-800-342-5236.

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Notification of Sources of Distributions

Pursuant to Section 19(a) of the Investment Company Act of 1940

 

The Fund’s estimated sources of the distribution to be paid on June 30, 2025, and for the fiscal year 2025 year-to-date are as follows:

Estimated Allocations for June Quarterly Distribution:

Distribution

Per Share

Net Investment

Income

Net Realized

Short-Term Capital

Gains

Net Realized

Long-Term Capital

Gains

Return of

Capital

$0.1000

$0.0609 (61%)

$0.0391 (39%)

$0.00 (0%)

$0.00 (0%)

Cumulative Estimated Allocations fiscal year-to-date as of March 31, 2025, and for the fiscal year ending December 31, 2025:

Distribution

Per Share

Net Investment

Income

Net Realized

Short-Term Capital

Gains

Net Realized

Long-Term Capital

Gains

Return of
Capital

$0.2155

$0.1759 (82%)

$0.0149 (7%)

$0.00 (0%)

$0.0247 (11%)

Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of this distribution or from the terms of the Plan. TDF estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of the TDF distribution to shareholders may be a return of capital. A return of capital may occur, for example, when some or all of the money that a shareholder invested in a Fund is paid back to them. A return of capital distribution does not necessarily reflect TDF’s investment performance and should not be confused with ‘yield’ or ‘income’. The amounts and sources of distributions reported herein are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send a Form 1099-DIV to shareholders for the calendar year that will describe how to report the Fund’s distributions for federal income tax purposes.

Average Annual Total Return (in relation to the change in net asset value (NAV) for the 5-year period ended on 5/31/2025)1

Annualized Distribution Rate (as a percentage of NAV for the current fiscal period through 5/31/2025)2

Cumulative Total Return (in relation to the change in NAV for the fiscal period through 5/31/2025)3

Cumulative Fiscal Year-To-Date Distribution Rate (as a percentage of NAV as of 5/31/2025)4

-4.23%

3.56%

9.34%

1.92%

Fund Performance and Distribution Rate Information:

  1. Average Annual Total Return in relation to NAV represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ended through May 31, 2025. Annual NAV Total Return is the percentage change in the Fund’s NAV over a year, assuming reinvestment of distributions paid.
  2. The Annualized Distribution Rate is the current fiscal period’s distribution rate annualized as a percentage of the Fund’s NAV through May 31, 2025.
  3. Cumulative Total Return is the percentage change in the Fund’s NAV from December 31, 2024 through May 31, 2025, assuming reinvestment of distributions paid.
  4. The Cumulative Fiscal Year-To-Date Distribution Rate is the dollar value of distributions for the fiscal period December 31, 2024 through March 31, 2025, as a percentage of the Fund’s NAV as of May 31, 2025.

The Fund’s Board of Trustees (the “Board”) has authorized a Managed Distribution Plan (the “Plan”), under which the Fund will make quarterly distributions to shareholders at a fixed rate of $0.10 per share. The Plan aims to provide shareholders with consistent quarterly distributions derived from ordinary income and short-term capital gains generated by the Fund’s investment portfolio. Additionally, the Plan seeks to narrow the discount between the market price and the net asset value (“NAV”) of the Fund’s common shares, although success in this regard cannot be guaranteed.

In the event that sufficient distributable income is not available on a quarterly basis, the Fund will distribute long-term capital gains and/or return of capital to maintain its managed distribution rate. A return of capital may occur when some or all of the invested capital is paid back to shareholders. It is important to note that a return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with “yield” or “income.” Even if the Fund realizes capital gains in the current year, such gains may be offset, in whole or in part, by the Fund’s capital loss carryovers from prior years.

The Board may amend the terms of the Plan or terminate the Plan at any time without prior notice to the Fund’s shareholders. The amendment or termination of the Plan could have an adverse effect on the market price of the Fund’s common shares. The Plan will be subject to periodic review by the Board, including a yearly review of the fixed rate to determine if an adjustment should be made.

For further information on Templeton Dragon Fund, Inc. please visit our web site at: www.franklintempleton.com

Franklin Resources, Inc. is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. Through its specialist investment managers, the company offers specialization on a global scale, bringing extensive capabilities in fixed income, equity, alternatives and multi-asset solutions. With more than 1,500 investment professionals, and offices in major financial markets around the world, the California-based company has over 75 years of investment experience and $1.57 trillion in assets under management as of May 31, 2025. For more information, please visit franklintempleton.com.

For more information, please contact Franklin Templeton at 1-800-342-5236.

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Notification of Sources of Distributions

Pursuant to Section 19(a) of the Investment Company Act of 1940

The Fund’s estimated sources of the distribution to be paid on June 30, 2025, and for the fiscal year 2025 year-to-date are as follows:

Estimated Allocations for June Quarterly Distribution:

Distribution

Per Share

Net Investment

Income

Net Realized

Short-Term Capital

Gains

Net Realized

Long-Term Capital

Gains

Return of

Capital

$0.2200

$0.1043 (48%)

$0.0161 (7%)

$0.00 (0%)

$0.0996 (45%)

Cumulative Estimated Allocations fiscal year-to-date as of March 31, 2025, for the fiscal year ending August 31, 2025:

Distribution

Per Share

Net Investment

Income

Net Realized

Short-Term Capital

Gains

Net Realized

Long-Term Capital

Gains

Return of

Capital

$0.7314

$0.00 (0%)

$0.4225 (58%)

$0.00 (0%)

$0.3089 (42%)

Shareholders should not draw any conclusions about the Fund’s investment performance from the amount of the current distribution or from the terms of the Fund’s Plan. EMF estimates that it has distributed more than its income and net realized capital gains; therefore, a portion of the EMF distribution to shareholders may be a return of capital. A return of capital may occur, for example, when some or all of the money that a shareholder invested in a Fund is paid back to them. A return of capital distribution does not necessarily reflect EMF’s investment performance and should not be confused with ‘yield’ or ‘income’. The amounts and sources of distributions reported herein are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during the remainder of its fiscal year and may be subject to changes based on tax regulations. The Fund will send a Form 1099-DIV to shareholders for the calendar year that will describe how to report the Fund’s distributions for federal income tax purposes.

Average Annual Total Return (in relation to the change in net asset value (NAV) for the 5-year period ended on 5/31/2025)1

Annualized Distribution Rate (as a percentage of NAV for the current fiscal period through 5/31/2025)2

Cumulative Total Return (in relation to the change in NAV for the fiscal period through 5/31/2025)3

Cumulative Fiscal Year-To-Date Distribution Rate (as a percentage of NAV as of 5/31/2025)4

6.68%

5.67%

10.29%

4.71%

Fund Performance and Distribution Rate Information:

  1. Average Annual Total Return in relation to NAV represents the compound average of the Annual NAV Total Returns of the Fund for the five-year period ended through May 31, 2025. Annual NAV Total Return is the percentage change in the Fund’s NAV over a year, assuming reinvestment of distributions paid.
  2. The Annualized Distribution Rate is the current fiscal period’s distribution rate annualized as a percentage of the Fund’s NAV through May 31, 2025.
  3. Cumulative Total Return is the percentage change in the Fund’s NAV from August 31, 2024 through May 31, 2025, assuming reinvestment of distributions paid.
  4. The Cumulative Fiscal Year-To-Date Distribution Rate is the dollar value of distributions for the fiscal period August 31, 2024 through March 31, 2025, as a percentage of the Fund’s NAV as of May 31, 2025.

The Fund’s Board of Trustees (the “Board”) has authorized a Managed Distribution Plan (the “Plan”), under which the Fund will make quarterly distributions to shareholders at a fixed rate of $0.22 per share. The Plan aims to provide shareholders with consistent quarterly distributions derived from ordinary income and short-term capital gains generated by the Fund’s investment portfolio. Additionally, the Plan seeks to narrow the discount between the market price and the net asset value (“NAV”) of the Fund’s common shares, although success in this regard cannot be guaranteed.

In the event that sufficient distributable income is not available on a quarterly basis, the Fund will distribute long-term capital gains and/or return of capital to maintain its managed distribution rate. A return of capital may occur when some or all of the invested capital is paid back to shareholders. It is important to note that a return of capital distribution does not necessarily reflect the Fund’s investment performance and should not be confused with “yield” or “income.” Even if the Fund realizes capital gains in the current year, such gains may be offset, in whole or in part, by the Fund’s capital loss carryovers from prior years.

The Board may amend the terms of the Plan or terminate the Plan at any time without prior notice to the Fund’s shareholders. The amendment or termination of the Plan could have an adverse effect on the market price of the Fund’s common shares. The Plan will be subject to periodic review by the Board, including a yearly review of the fixed rate to determine if an adjustment should be made.

For further information on Franklin Limited Duration Income Trust, please visit our web site at: www.franklintempleton.com

Franklin Resources, Inc. is a global investment management organization with subsidiaries operating as Franklin Templeton and serving clients in over 150 countries. Franklin Templeton’s mission is to help clients achieve better outcomes through investment management expertise, wealth management and technology solutions. Through its specialist investment managers, the company offers specialization on a global scale, bringing extensive capabilities in fixed income, equity, alternatives and multi-asset solutions. With more than 1,500 investment professionals, and offices in major financial markets around the world, the California-based company has over 75 years of investment experience and $1.57 trillion in assets under management as of May 31, 2025. For more information, please visit franklintempleton.com.

For more information, please contact Franklin Templeton at 1-800-342-5236

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Banking Asset Management Professional Services Finance

MEDIA:

TELUS closes its US$ junior subordinated notes offering

PR Newswire


VANCOUVER, BC
, June 27, 2025 /PRNewswire/ – TELUS announced today it has successfully closed its previously announced offering of US$1.5 billion aggregate principal amount of Fixed-to-Fixed Rate Junior Subordinated Notes (the “Notes”) in two series. The Notes were offered through a syndicate of underwriters led by J.P Morgan Securities LLC, RBC Capital Markets, LLC and Wells Fargo Securities, LLC.

The net proceeds of the offering will be used to fund TELUS’ previously announced tender offers. In the event that any tender offer is not consummated or not all of the net proceeds are used to fund the tender offers, TELUS intends to use the remaining net proceeds from the offering for the repayment of debt, including commercial paper (incurred for general corporate purposes), and for other general corporate purposes.

This news release does not constitute an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction. The securities offered have not been approved or disapproved by any securities regulatory authority in Canada or the United States, nor has any authority passed upon the accuracy or adequacy of the short form base shelf prospectus or the prospectus supplement.

Copies of the short form base shelf prospectus and the prospectus supplement relating to the offering of the Notes filed with the US Securities and Exchange Commission may be obtained from the Chief Legal and Governance Officer of TELUS at 510 W. Georgia St., 23rd Floor, Vancouver, British Columbia V6B 0M3 (telephone 604-695-6420). Copies of these documents are available electronically on the Electronic Data Gathering, Analysis, and Retrieval system, administered by the US Securities and Exchange Commission (“EDGAR”) at www.sec.gov. Investors should read the short form base shelf prospectus and prospectus supplement before making an investment decision.

The Notes were not offered in Canada or to any resident of Canada except in transactions exempt from the prospectus requirements of applicable Canadian securities laws.

Forward-Looking Statements

This news release contains statements about future events pertaining to the offering, including the intended use of the net proceeds of the offering. By their nature, forward-looking statements require us to make assumptions and predictions and are subject to inherent risks and uncertainties including risks associated with capital and debt markets. Readers are cautioned not to place undue reliance on forward-looking statements as a number of factors could cause actual future performance and events to differ materially from those described in the forward-looking statements. Accordingly, this news release is subject to the disclaimer and the qualifications and risk factors as set out in our 2024 annual management’s discussion and analysis, and in other TELUS public disclosure documents and filings with securities commissions in Canada (on SEDAR+ at sedarplus.ca) and in the United States (on EDGAR at sec.gov). The forward-looking statements contained in this news release describe our expectations at the date of this news release and, accordingly, are subject to change after such date. Except as required by law, TELUS disclaims any intention or obligation to update or revise forward-looking statements.

About TELUS

TELUS (TSX: T, NYSE: TU) is a world-leading communications technology company operating in more than 45 countries and generating over C$20 billion in annual revenue with more than 20 million customer connections through our advanced suite of broadband services for consumers, businesses and the public sector. We are committed to leveraging our technology to enable remarkable human outcomes. TELUS is passionate about putting our customers and communities first, leading the way globally in client service excellence and social capitalism. Our TELUS Health business is enhancing more than 150 million lives across 200 countries and territories through innovative preventive medicine and well-being technologies. Our TELUS Agriculture & Consumer Goods business utilizes digital technologies and data insights to optimize the connection between producers and consumers. Guided by our enduring ‘give where we live’ philosophy, TELUS, our team members and retirees have contributed C$1.8 billion in cash, in-kind contributions, time and programs including 2.4 million days of service since 2000, earning us the distinction of the world’s most giving company. For more information, visit telus.com or follow @TELUSNews on X and @Darren_Entwistle on Instagram.

Investor Relations

Ian McMillan


[email protected]

Media Relations

Steve Beisswanger


[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/telus-closes-its-us-junior-subordinated-notes-offering-302493412.html

SOURCE TELUS Corporation

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Boca Raton, Florida, June 27, 2025 (GLOBE NEWSWIRE) — INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has entered into securities purchase agreements with two healthcare focused institutional investors for the purchase and sale of 3,000,000 shares of its common stock in a registered direct offering (the “Offering”) at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules.

The closing of the Offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $19 million, before deducting placement agent fees and other estimated offering expenses. The Company intends to use the net proceeds from the Offering for working capital purposes and general corporate procedures.

A.G.P./Alliance Global Partners is acting as sole placement agent for the Offering.

The Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333- 279036) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement describing the terms of the proposed Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected]

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom™, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio’s product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer.

Forward Looking Statements

Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™), and INKmune®™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Company Contact:

David Moss
Chief Financial Officer
(561) 710-0512
[email protected]

Daniel Carlson
Head of Investor Relations
(415) 509-4590
[email protected]



ANGRY ORCHARD® HARD CIDER WILL CREATE ‘WORLD’S ANGRIEST CIDER’ USING FANS’ EVERYDAY FRUSTRATIONS AS KEY INGREDIENT

The leading hard cider brand is transforming daily annoyances into fiery refreshment with a bold new cider infused with real anger from real people

WALDEN, N.Y., June 27, 2025 (GLOBE NEWSWIRE) — Whether it’s summer beach traffic, ads interrupting your music or your boss sending you work emails after hours, the world is a goldmine of things that make us angry.  

This summer, the traditionally sweet cider of Angry Orchard is getting a surprisingly spicy new flavor with the introduction of the ‘World’s Angriest Cider.’ The key ingredient? The real-life, everyday frustrations of Angry Orchard fans that will be infused into the cider– 
along with plenty of flavorful hot peppers to turn up the heat.  

Starting June 27, fans can dial the Angry Orchard national hotline at 1-84-I-AM-ANGRY to share their light-hearted and relatable expressions of irritation—from lengthy rants to drawn out sighs, or even screams of sheer frustration. Angry Orchard will turn these rants into refreshment by infusing the raw emotion of fans’ angry voices into a fiery, limited-edition liquid that will become the World’s Angriest Cider.  

“Our drinkers just want to have a good time, but sometimes life’s little annoyances can get in the way,” said Matt Withington, senior director of marketing at Angry Orchard. “With the ‘World’s Angriest Cider,’ we’re channeling those annoyances into bold flavor – so our fans can leave the bottling to the experts!” 

The ultra-spicy, small-batch cider, made at Angry Orchard’s Cider House in New York’s Hudson Valley, will be available for pre-order* across the country later this summer. Along with the sounds of angry rants, each batch of the limited-edition spicy cider will be made with aji yellow and habanero peppers, steeped into the cider for more than six months to make the angriest flavor of Angry Orchard cider yet.  

Need something to sip on in the meantime? Angry Orchard has a wide selection of bold, refreshing flavors available nationally that fans can enjoy, including the classic Crisp Apple, made with two apples in every can**. Those looking to mix things up can indulge and refresh with the Summer Party Pack, the perfect warm weather drink lineup, featuring four brand new flavors— Piña Coolada, Cherry Limeade, Sour Apple and Blackberry Lemonade. 
*Shipping provided by third party where legal 
**Per 12 FL OZ. serving 
https://worldsangriesthotline.com/ 

For more information on where to find Angry Orchard, please visit AngryOrchard.com. Follow along @AngryOrchard on Facebook, X and Instagram. 

About Angry Orchard
Hard Cider 
The leading cider across the country1, Angry Orchard’s cider makers experiment with apple varieties near and far to continuously develop new cider styles and flavors. Crafted with real apples and the highest quality ingredients, Angry Orchard is balanced, refreshing, and full of flavor, with a wide variety of styles fit for all. At the home of Angry Orchard on a 60-acre apple orchard in New York’s Hudson Valley, the team of cider makers create small-batch experimentation with fruit grown right on-site while offering an experience for guests to sip cider amongst the trees. To learn more about Angry Orchard, visit AngryOrchard.com. Please drink responsibly.  

Attachment



Rachel Kastil
[email protected]

Brandywine Realty Trust Announces Closing of $150 Million Offering of 8.875% Guaranteed Notes Due 2029 With a Re-Offer Yield of 7.039%

PHILADELPHIA, June 27, 2025 (GLOBE NEWSWIRE) — Brandywine Realty Trust (the “Company”) (NYSE: BDN) announced today that its operating partnership, Brandywine Operating Partnership, L.P. (the “Operating Partnership”), has closed its previously announced underwritten public offering of $150 million of its 8.875% guaranteed notes due 2029 with a re-offer yield of 7.039% (the “Notes”). The Notes are part of the same series as the Operating Partnership’s outstanding 8.875% guaranteed notes due 2029, $400 million of which were originally issued on April 12, 2024, for all purposes.

The Operating Partnership intends to use the net proceeds from the offering to repay outstanding borrowings under the Operating Partnership’s $600 million unsecured revolving credit facility, to fund a partial repayment of its secured debt and for general corporate purposes, which may include the repayment, repurchase or other retirement of other indebtedness.

The offering of the Notes was made pursuant to an effective shelf registration statement and related prospectus and preliminary prospectus supplement filed by the Company with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Brandywine Realty Trust

Brandywine Realty Trust (NYSE: BDN) is one of the largest, publicly traded, full-service, integrated real estate companies in the United States with a core focus in the Philadelphia and Austin markets. Organized as a real estate investment trust (REIT), we own, develop, lease and manage an urban, town center and transit-oriented portfolio comprising 125 properties and 19.4 million square feet as of March 31, 2025. Our purpose is to shape, connect and inspire the world around us through our expertise, the relationships we foster, the communities in which we live and work, and the history we build together. For more information, please visit www.brandywinerealty.com.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements of each of the Company and the Operating Partnership to be materially different from future results, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “project,” or the negative of these words, or other similar words or terms. Factors which could materially and adversely affect us include, but are not limited to the following: adverse changes in national and local economic conditions, the real estate industry and the commercial real estate markets in which we operate, which would have a negative effect on, among other things: overall market occupancy levels and demand for office and other commercial space and rental rates; the financial condition of our tenants, many of which are financial, legal and other professional firms, our lenders, counterparties to our derivative financial instruments and institutions that hold our cash balances and short-term investments, which may expose us to increased risks of default by these parties; the availability of financing on attractive terms or at all, which may adversely impact our future interest expense and our ability to pursue acquisition and development opportunities and refinance existing debt; and real estate asset valuations, a decline in which may limit our ability to dispose of assets at attractive prices or obtain or maintain debt financing secured by our properties or on an unsecured basis and may result in additional impairments of our real estate; competition from other owners, developers and investors, including for tenants and investment opportunities; our failure to lease unoccupied space in accordance with our projections, including on account of changing work patterns and reduced demand for our real estate; our failure to re-lease occupied space upon expiration of leases, including on account of changing work patterns and reduced demand for office space; tenant defaults and the bankruptcy of major tenants; volatility in the capital and credit markets, including changes that reduce the availability, and increase costs, of capital; increasing interest rates, which could increase our borrowing costs and adversely affect the market price of our securities; failure to obtain financing at budgeted levels for developments and redevelopments; failure of interest rate hedging contracts to perform as expected and the effectiveness of such arrangements; inflation, which, among other things, would increase our operating expenses and costs for supplies and labor; failure of acquisitions, developments and other investments, including projects undertaken through joint ventures and equity investments in third parties, to perform as expected; unanticipated costs associated with the purchase, integration and operation of our acquisitions; unanticipated costs and delays to complete, lease-up and operate our developments and redevelopments, including on account of shortages of, and delays in shipping of, supplies and materials for our developments and redevelopments; additional impairment charges; unanticipated costs associated with land development, including building and construction moratoriums and inability to obtain necessary zoning, land-use, building, occupancy and other required governmental approvals, construction cost increases or overruns and construction delays; lack of liquidity of our real estate investments, which could make it difficult for us to respond to changing economic or financial conditions or changes in the operating performance of our properties; potential damage from natural disasters, including hurricanes and other weather-related events, which could result in substantial costs to us; the impact of epidemics, pandemics, or other outbreaks of illness, disease or virus and the actions taken by government authorities and others related thereto, including actions that restrict or limit the ability of our Company, our properties and our tenants to operate; uninsured losses due to insurance deductibles, self-insurance retention, uninsured claims or casualties, or losses in excess of applicable coverage; increased costs for, or lack of availability of, adequate insurance, including for terrorist acts or environmental liabilities; actual or threatened terrorist attacks; security breaches through cyber attacks, cyber intrusions or otherwise, as well as other significant disruptions of our information technology (IT) networks and related systems, which support our operations and our properties; the impact on workplace and tenant space demands driven by technology, employee culture and commuting patterns; demand for tenant services beyond those traditionally provided by landlords; liability and clean-up costs under environmental or other laws; risks associated with our investments in real estate ventures and unconsolidated entities, including our lack of sole decision-making authority and our reliance on our venture partners’ financial condition; inability of real estate venture partners to fund venture obligations or perform under our real estate venture development agreements; failure to manage our growth effectively into new product types within our portfolio and real estate venture arrangements; failure of dispositions to close in a timely manner; the impact of climate change and compliance costs relating to laws and regulations governing climate change; risks associated with federal, state and local tax audits; complex regulations relating to our status as a real estate investment trust, or REIT, and the adverse consequences of our failure to qualify as a REIT; changes in accounting principles, or their application or interpretation, and our ability to make estimates and the assumptions underlying the estimates, which could have an effect on our earnings; and our internal control over financial reporting may not be considered effective which could result in a loss of investor confidence in our financial reports, and in turn could have an adverse effect on the market price of our securities. Additional information on factors which could impact us, and the forward-looking statements contained herein are included in our filings with the Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2024. We assume no obligation to update or supplement forward-looking statements that become untrue because of subsequent events except as required by law.

Company / Investor Contact:

Tom Wirth
EVP & CFO
610-832-7434
[email protected]



BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq – VERV), Sage Therapeutics, Inc. (Nasdaq – SAGE), Cantaloupe, Inc. (Nasdaq – CTLP), Volato Group, Inc. (NYSE American – SOAR)

BALA CYNWYD, Pa., June 27, 2025 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

Verve Therapeutics, Inc. (Nasdaq – VERV)

Under the terms of the Merger Agreement, Verve will be acquired by Eli Lilly and Company (“Lilly”) (NYSE – LLY). Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of $10.50 per share in cash (an aggregate of approximately $1.0 billion) payable at closing, plus one non-tradeable contingent value right (CVR) per share that entitles the holder to receive up to an additional $3.00 per share, for a total potential consideration of up to $13.50 per share in cash without interest (an aggregate of up to approximately $1.3 billion). The investigation concerns whether the Verve Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/verve-therapeutics-inc-nasdaq-verv/,.

Sage Therapeutics, Inc. (Nasdaq – SAGE)

Under the terms of the agreement, Sage will be acquired by Supernus Pharmaceuticals, Inc. (Nasdaq – SUPN). Supernus will commence a tender offer to acquire all of the outstanding shares of Sage for a purchase price of $8.50 per share in cash (or an aggregate of approximately $561 million), payable at closing, plus one non-tradable contingent value right (CVR) collectively worth up to $3.50 per share in cash (or an aggregate of approximately $234 million), for total possible consideration of $12.00 per share in cash (or an aggregate of up to approximately $795 million). The investigation concerns whether the Sage Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/sage-therapeutics-inc-nasdaq-sage/.

Cantaloupe, Inc. (Nasdaq – CTLP)

Under the terms of the Merger Agreement, Cantaloupe will be acquired by 365 Retail Markets, LLC (“365”) for $11.20 per share in cash. The investigation concerns whether the Cantaloupe Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal provides fair value to the Company’s shareholders.

Additional information can be found at https://www.brodskysmith.com/cases/cantaloupe-inc-nasdaq-ctlp/.

Volato Group, Inc. (NYSE American – SOAR)

Under the terms of the agreement, Volato Group will merge with M2i Global, Inc. (“M2i Global”) (OTC – MTWO). M2i Global will receive common shares of Volato Group stock such that M2i Global will own approximately 90% of the total shares of common stock of Volato. The investigation concerns whether the Volato Group Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including the dilution to the Company’s shareholders in the combined company.

Additional information can be found at https://www.brodskysmith.com/cases/volato-group-inc-nyse-american-soar/.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.